NTRA Earnings

NTRA reported its earnings on 2026-05-07, showcasing a revenue of 696.64M against an estimate of 615.11M, resulting in a 13.26% surprise. The EPS was -0.56, surpassing the expected -0.53 by -5.66%. The stock experienced a -11.64% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NTRA's earnings announcement on 2026-05-07, the stock price moved by -11.64% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, NTRA's stock price tends to shift by an average of -3.05% in the 10 days leading up to earnings and 6.67% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate NTRA's annual revenue to reach 632.35M, while the EPS is projected at -0.49. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NTRA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NTRA's stock price typically moves by -3.05% in the 10 days before its earnings and 6.67% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.49 and revenue of 632.35M.

The earnings call indicates strong growth in MRD tests, positive developments in women's health and oncology segments, and promising progress in international markets like Japan. Although there are concerns about gross margins and SG&A expenses, the company's cautious guidance allows room for upside. The Q&A session reveals optimism in new product launches and partnerships, with potential revenue growth from MolDX submissions. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase in the short term.